Abstract
Reactive oxygen species (ROS) are considered to be a main cause for cancer development, but they can also be used for cancer eradication. Because of this dual nature of ROS action, both antioxidant and prooxidant therapeutic agents have been developed and some have shown clinical promise. Selective uptake of porphyrins by malignant cells has for a long time been used for tumor imaging and for targeted delivery of ROS. Redox-active Mn porphyrins can act both as antioxidants and as prooxidants, and may thus be used in anticancer therapy. Porphyrins, which chelate redox inactive metals, for example Zn, demonstrate photo-sensitizing activity and thus can produce singlet oxygen and other reactive oxygen species in cancer cells on irradiation with visible light. Here we review the properties of Zn(II) N-alkylpyridylporphyrin-based photosensitizers, and their ability to damage selected cellular targets.
Keywords: Ortho, meta, and para isomeric Zn(II) N-alkylpyridylporphyrins, photosensitizer, singlet oxygen, photodynamic therapy, cell signaling functions, hyperproliferative tissues, tetrapyrrole ring, lipophilicity/hydrophilicity, methylpyridylporphyrins, transmembrane movement, lysosomes, Immunoblots, hydrophilic analogs, erythrocyte membrane, hydrophobicity, lipophilic components
Anti-Cancer Agents in Medicinal Chemistry
Title: The Potential of Zn(II) N-Alkylpyridylporphyrins for Anticancer Therapy
Volume: 11 Issue: 2
Author(s): Ludmil Benov, James Craik and Ines Batinic-Haberle
Affiliation:
Keywords: Ortho, meta, and para isomeric Zn(II) N-alkylpyridylporphyrins, photosensitizer, singlet oxygen, photodynamic therapy, cell signaling functions, hyperproliferative tissues, tetrapyrrole ring, lipophilicity/hydrophilicity, methylpyridylporphyrins, transmembrane movement, lysosomes, Immunoblots, hydrophilic analogs, erythrocyte membrane, hydrophobicity, lipophilic components
Abstract: Reactive oxygen species (ROS) are considered to be a main cause for cancer development, but they can also be used for cancer eradication. Because of this dual nature of ROS action, both antioxidant and prooxidant therapeutic agents have been developed and some have shown clinical promise. Selective uptake of porphyrins by malignant cells has for a long time been used for tumor imaging and for targeted delivery of ROS. Redox-active Mn porphyrins can act both as antioxidants and as prooxidants, and may thus be used in anticancer therapy. Porphyrins, which chelate redox inactive metals, for example Zn, demonstrate photo-sensitizing activity and thus can produce singlet oxygen and other reactive oxygen species in cancer cells on irradiation with visible light. Here we review the properties of Zn(II) N-alkylpyridylporphyrin-based photosensitizers, and their ability to damage selected cellular targets.
Export Options
About this article
Cite this article as:
Benov Ludmil, Craik James and Batinic-Haberle Ines, The Potential of Zn(II) N-Alkylpyridylporphyrins for Anticancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/187152011795255975
DOI https://dx.doi.org/10.2174/187152011795255975 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer
Current Stem Cell Research & Therapy The Effects of All-Trans-Retinoic Acid on Cell Cycle and Alkaline Phosphatase Activity in Pancreatic Cancer Cells
Medicinal Chemistry Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy DNA Double Strand Breaks Repair Inhibitors: Relevance as Potential New Anticancer Therapeutics
Current Medicinal Chemistry Cellular Redox Modulator, ortho Mn(III) meso-tetrakis(N-n-Hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP5+ in the Treatment of Brain Tumors
Anti-Cancer Agents in Medicinal Chemistry Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry Anticoagulant and Fibrinolytic Drugs – Possible Agents in Treatment of Lung Cancer?
Anti-Cancer Agents in Medicinal Chemistry When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design Malignant Pleural Mesothelioma in 2011. Is there a Gold Standard Therapy?
Current Respiratory Medicine Reviews Conserved Domains, Residues, WebLogo and Active Sites of Caspase- Cascades Related to Apoptotic Signaling Pathway
Current Bioinformatics Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Ruthenium Complex as Enzyme Modulator: Modulation of Lactate Dehydrogenase by a Novel Ruthenium(II) Complex Containing 4-Carboxy N-Ethylbenzamide as a Ligand
Current Enzyme Inhibition Editorial (Thematic Issue: Helicobacter pylori Eradication Therapy: Advantages and Disadvantages)
Current Pharmaceutical Design The Application of DNA Microarrays to the Study of Cancer
Current Genomics The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro
Current Drug Delivery Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Treatment of Nasopharyngeal Carcinoma: Therapeutic Management and Future View of Epstein-Barr Virus-Targeting Treatment
Current Cancer Therapy Reviews Anti-Tumorigenic Effects of Resveratrol in Lung Cancer Cells Through Modulation of c-FLIP
Current Cancer Drug Targets